Ultragenyx to Participate in Investor Conferences in September
2024年8月30日 - 5:30AM
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical
company focused on the development and commercialization of novel
therapies for serious rare and ultrarare genetic diseases, today
announced participation in three upcoming investor conferences.
Morgan Stanley 22nd
Annual Global Healthcare Conference (New York,
NY)
- Wednesday, September 4, 2024, Emil
Kakkis, M.D., Ph.D., CEO and President, will participate in a
fireside chat and host 1x1 meetings.
Cantor Global Healthcare Conference (New York,
NY)
- Tuesday, September 17, 2024, Emil
Kakkis and Howard Horn, Chief Financial Officer, will participate
in a fireside chat and host 1x1 meetings.
Bank of America Global Healthcare Conference (London,
UK)
- Wednesday, September 18, 2024, Eric
Crombez, M.D., Chief Medical Officer and Joshua Higa, Vice
President, Investor Relations, will participate in a fireside chat
and host 1x1 meetings.
The live and archived webcast of the fireside chats will be
accessible from the company’s website at
https://ir.ultragenyx.com/events-presentations.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing
novel products to patients for the treatment of serious rare and
ultrarare genetic diseases. The company has built a diverse
portfolio of approved therapies and product candidates aimed at
addressing diseases with high unmet medical need and clear biology
for treatment, for which there are typically no approved therapies
treating the underlying disease.
The company is led by a management team experienced in the
development and commercialization of rare disease therapeutics.
Ultragenyx’s strategy is predicated upon time- and cost-efficient
drug development, with the goal of delivering safe and effective
therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's
website at: www.ultragenyx.com.
Contacts – Ultragenyx Pharmaceutical, Inc.
InvestorsJoshua Higa ir@ultragenyx.com
Ultragenyx Pharmaceutical (NASDAQ:RARE)
過去 株価チャート
から 8 2024 まで 9 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
過去 株価チャート
から 9 2023 まで 9 2024